Dizal Pharmaceutical Co., Ltd (Ticker: 688192) is a clinical stage biopharmaceutical company. The company aims to develop first-in-class and groundbreaking new medicines to address unmet medical needs around the world. Deep-rooted in translational science and molecular design, it has established an internationally competitive portfolio of six assets with two in global pivotal studies.